Markets:

Overview

News

Currencies

International

Treasuries

Milestone Pharmaceuticals Inc. - Common Shares (NQ:MIST)

0.5200 -0.1400 (-21.21%)

Delayed Quote Updated: 4:00 PM EST, Nov 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Milestone Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 Next >

Milestone (MIST) Q3 2026 Earnings Call Transcript ↗

Today 14:45 EST

Sales force shift and cost cuts reshape Milestone's launch strategy.

Via The Motley Fool

Topics Earnings

Milestone Pharmaceuticals Q3 Earnings Call Highlights ↗

Today 11:14 EST

Milestone Pharmaceuticals (NASDAQ:MIST) plans to cut operating expenses by approximately 30% as it seeks to extend its cash runway while building sales of CARDAMYST and advancing a late-stage clinical...

Via MarketBeat

Topics Earnings

Milestone (MIST) Q2 2026 Earnings Call Transcript ↗

August 19, 2026

CARDAMYST prescriptions surged fourfold as insurance coverage doubled to 50%.

Via The Motley Fool

Topics Earnings

Milestone Pharmaceuticals (NASDAQ:MIST) Reports First Revenue with Q4 2025 Earnings, Beats Estimates ↗

March 20, 2026

Via Chartmill

Topics Earnings

Milestone Pharmaceuticals Q2 Earnings Call Highlights ↗

August 12, 2026

Milestone Pharmaceuticals (NASDAQ:MIST) reported early commercial traction for CARDAMYST following its mid-February launch, while advancing a pivotal Phase III study of etripamil in atrial fibrillation...

Via MarketBeat

Topics Earnings

Milestone (MIST) Q1 2026 Earnings Transcript ↗

June 01, 2026

Milestone (MIST) Q1 2026 Earnings Transcript

Via The Motley Fool

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

May 14, 2026

From Milestone Pharmaceuticals Inc.

Via GlobeNewswire

Why Milestone Pharmaceuticals Stock Wilted on Wednesday ↗

May 13, 2026

The biotech fell well short of analyst projections in the first quarter.

Via The Motley Fool

Milestone Pharmaceuticals Q1 Earnings Call Highlights ↗

May 13, 2026

Milestone Pharmaceuticals (NASDAQ:MIST) said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal...

Via MarketBeat

Topics Earnings

Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales ↗

May 13, 2026

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) reported first-quarter earnings on Wednesday before the market opened.

Via Benzinga

Stay updated with the stocks that are on the move in today's pre-market session. ↗

May 13, 2026

Via Chartmill

What's going on in today's session ↗

March 20, 2026

Via Chartmill

Synergy CHC Corp. (NASDAQ: SNYR) Expands FOCUSfactor® Beverage Platform Further Building Shareholder Value – IMG, YCBD, SURG, URG Inside

December 15, 2025

Via AB Newswire

MIST Stock Soars Pre-Market After FDA Approves First Commercial Product – Retail Remains Bullish, Dismisses ‘Sell The News’ Concerns ↗

December 15, 2025

Milestone stated in its announcement that the approval of Cardamyst opens up an addressable market of more than two million Americans who suffer from PSVT.

Via Stocktwits

Monday's pre-market session: top gainers and losers ↗

December 15, 2025

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

December 12, 2025

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Milestone Pharmaceuticals (NASDAQ:MIST) Posts Narrower-Than-Expected Q3 Loss as Key FDA Decision Looms ↗

November 12, 2025

Milestone Pharmaceuticals beat Q3 earnings estimates, with a narrower loss. The stock rose as investors await the December 2025 FDA decision for its lead drug, CARDAMYST™.

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

July 11, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge ↗

July 11, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 11, 2025

Via Benzinga

Which stocks are moving on Friday? ↗

July 11, 2025

Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Why Is Milestone Pharmaceuticals Stock Plunging On Friday? ↗

July 11, 2025

FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support potential PSVT treatment launch.

Via Benzinga

Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings ↗

July 11, 2025

Via Benzinga

Topics Stocks

There are notable gap-ups and gap-downs in today's session. ↗

July 11, 2025

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

July 11, 2025

The US market session of Friday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 11, 2025

Via Benzinga

Top movers analysis one hour before the close of the markets on 2025-03-28: top gainers and losers in today's session. ↗

March 28, 2025

Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Top movers in Friday's session ↗

March 28, 2025

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.

Via Chartmill

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive ↗

March 28, 2025

The FDA said an inspection is required at a facility where the company performed release testing for the product to ensure it complies with Current Good Manufacturing Practices.

Via Stocktwits

12 Health Care Stocks Moving In Friday's Intraday Session ↗

March 28, 2025

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.